IMV (NYSE:IMV) Earns Buy Rating from HC Wainwright
HC Wainwright restated their buy rating on shares of IMV (NYSE:IMV) in a report issued on Monday, AnalystRatings.com reports. They currently have a $11.50 price target on the stock.
A number of other research firms have also recently commented on IMV. Raymond James set a $10.00 price target on shares of IMV and gave the stock an outperform rating in a report on Thursday, November 7th. Wells Fargo & Co initiated coverage on shares of IMV in a report on Monday, October 28th. They issued a market perform rating on the stock. Finally, Zacks Investment Research cut shares of IMV from a buy rating to a hold rating in a report on Saturday, October 26th. One analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $9.60.
Shares of NYSE:IMV traded up $0.08 during mid-day trading on Monday, reaching $2.49. The company had a trading volume of 5,700 shares, compared to its average volume of 19,652. The company’s 50-day moving average price is $2.66 and its 200-day moving average price is $3.12. IMV has a one year low of $2.25 and a one year high of $7.07.
A number of hedge funds have recently modified their holdings of the business. Hartford Financial Management Inc. raised its holdings in IMV by 9.6% during the 3rd quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock valued at $94,000 after acquiring an additional 3,348 shares during the period. Royal Bank of Canada raised its holdings in IMV by 3.6% during the 2nd quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock valued at $288,000 after acquiring an additional 3,453 shares during the period. Citadel Advisors LLC bought a new stake in IMV during the 2nd quarter valued at $37,000. Bank of Montreal Can raised its holdings in IMV by 17.5% during the 2nd quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock valued at $260,000 after acquiring an additional 13,228 shares during the period. Finally, Morgan Stanley raised its holdings in IMV by 260.5% during the 2nd quarter. Morgan Stanley now owns 90,368 shares of the company’s stock valued at $264,000 after acquiring an additional 65,300 shares during the period.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.